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64 Poster Session Iat transplantation.Results:NHLwas classified as aggressive in 270
patients (168 diffuse large B-cell lymphoma, 58 mantle cell lym-
phoma, 44 peripheral T cell lymphoma), and as indolent in 107 pa-
tients (follicular lymphoma). In the allo-HSCT group (related
donor: n 5 122, unrelated donor: n 5 50), 141 patients (median
age: 47 years old, range 18–64) underwent full-intensity condition-
ing (FIC) and 31 (median age: 58 years old, range 44–71) reduced-
intensity conditioning (RIC). Overall survival (OS) at 5-year in
chemosensitive patients was 46.2% (95% CI, 33.1–59.3) in the
allo-HSCT group (n 5 63) and 41.0% (30.7–51.3) in the auto-
HSCT group (n 5 176). OS in chemorefractory patients was
35.0% (5-year OS, 25.2–44.8) with survival plateau in the allo-
HSCT group (n 5 109) but only 7.4% (4-year OS, 0–20.3) in the
auto-HSCT group (n 5 29). In multivariate analysis using a Cox
hazard model for the entire cohort, chemorefractory disease (Haz-
ard ratio [HR], 1.73; 95%CI, 1.25–2.39; p5 0.001) and age over 50
(HR, 1.57; 95%CI, 1.19–2.07; p 5 0.001) were identified as signif-
icant risk factors on progression-free survival (PFS). In chemore-
fractory indolent NHL, patients with RIC had a better outcome
than auto-HSCT (p 5 0.016) or FIC (p 5 0.083), with 5-year
PFS of 56.1% (26.2–86.0) in RIC, 0% in auto-HSCT and 20.4%
(2.6–38.2) in FIC.Conclusions: Allo-HSCT has curative potential
for patients even in chemorefractory NHL. RIC for indolent NHL
provided significant PFS for patients even with chemorefractory
disease, and merits further investigation.172
PHASE I STUDY OF VACCINATIONWITH DENDRITIC CELLMYELOMA FU-
SIONS
Avigan, D.1, Rosenblatt, J.1, Vasir, B.2, Wu, Z.2, Bissonnette, A.2,
MacNamara, C.1, Uhl, L.1, Lenahan, C.1, Miller, K.1, Joyce, R.1,
Levine, J.D.1, Lowe, K.1, Donbagoda, D.1, Richardson, P.2,
Anderson, K.2, Munshi, N.2, Kufe, D.2 1Beth Israel Deaconess Medical
Center; 2Dana Farber Cancer Institute.
Wehave developed a cancer vaccine in which patient derived my-
eloma cells are fused with autologous dendritic cells (DCs). In this
way, multiple tumor antigens are presented in the context of DC de-
rived costimulatory molecules. We are conducting a phase I trial in
which multiple myeloma (MM) patients undergo serial vaccination
with DC/myeloma fusions in conjunction with GM-CSF. To date,
16 patients have been enrolled and 15 have undergone therapy. Pa-
tients underwent leukapheresis and DCs were generated from ad-
herent mononuclear cells cultured for 5 days with GM-CSF and
IL-4 and matured by exposure to TNFa. The mean yield of DCs
was 1.23  108 cells with a mean viability of 88%. Patient derived
MM cells were isolated from bone marrow aspirates. The mean
yield of MM cells was 92.5  106 cells with a mean viability of
90%. Fusion cells were generated by coculture of DCs with MM
cells in the presence of polyethylene glycol. Fusion cells were quan-
tified by determining the percentage of cells that co-expressed
unique DC and MM antigens. Mean fusion efficiency and viability
was 40% and 84%, respectively. As a measure of immunologic po-
tency, DC/MM fusions stimulated allogeneic T cell proliferation,
with mean stimulation indexes of 48, 36, and 9 for the DC, fusion
and MM cell populations, respectively. To date, 15 patients have
completed vaccination at a dose of 1–5  106 fusion cells. Adverse
events potentially related to vaccine included injection site reac-
tions, edema, rash, fever, chills, fatigue, myalgias, pruritis, and diar-
rhea. 1 patient with a history of deep venous thrombosis (DVT)
developed a DVT and pulmonary embolus of uncertain relation
to the vaccine. To date, 6/9 evaluable patients have demonstrated
immunologic response, defined by at least 2 fold increase in IFNg
expression by CD4 and/or CD8 T cells in response to ex vivo expo-
sure to autologous tumor lysate. Vaccination was associated with an
increase in circulating tumor specific T cells as evidenced by an in-
crease in CD81 cells binding the MUC1 tetramer. Humoral im-
mune responses are being assessed by SEREX analysis. 3 patients
have ongoing stable disease at 3.5, 6, and 19 months following their
initial vaccine. 6 patients demonstrated disease stability with subse-
quent progression ranging from 9weeks to 8months following their
first vaccine. Vaccination with DC/MM fusions has been well toler-
ated, associated with immunologic response, and disease stabiliza-
tion in a majority of patients with MM.173
STEM-CELL COLLECTION PRIOR TO AUTOLOGOUS STEM CELL TRANS-
PLANTATION IS IMPROVED BY CYCLOPHOSPHAMIDE IN LENALIDO-
MIDE-TREATED PATIENTS WITH MULTIPLE MYELOMA
Mark, T.1, Jayabalan, D.1, Stern, J.1, Furst, J.1, Rambo, A.1,
Pearse, R.N.1, Harpel, J.1, Shore, T.1, Schuster, M.1, Leonard, J.P.1,
Christos, P.J.2, Coleman, M.1, Niesvizky, R.1 1Weill Medical College
of Cornell University, New York, NY; 2Weill Medical College of Cornell
University, New York, NY.
Introduction:Recent studies discuss difficulty in collecting stem
cells in multiple myeloma (MM) patients receiving lenalidomide-
based induction therapy using filgastrim (granulocyte-colony stim-
ulating factor [G-CSF]) in preparation for autologous stem cell
transplantation (ASCT). It has also been suggested that treatment
time beyond 4–6 cycles might hinder collection yields.Aim:To de-
termine if addition of cyclophosphamide (CTX) to G-CSF as a mo-
bilization regimen could rescue collection of adequate stem cells for
at least two ASCTs in patients who had induction therapy with the
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/Dexa-
methasone) regimen. Method: Each 28-day cycle, patients re-
ceived: clarithromycin 500 mg po BID for days 1–28,
lenalidomide 25 mg po daily for days 1–21, and dexamethasone
40 mg po weekly on days 1, 8, 15, and 21. Patients were treatment
naive, with Stage II or III MM by Durie-Salmon criteria. Prior to
stem cell mobilization, BiRD therapy was held for a minimum of
14 days. Stem cell collection was performed after either G-CSF
alone at a dose 10mcg/kg/day for 5–10 consecutive days until a total
of 10  106/kg CD341 stem cells had been collected, or with addi-
tion of CTX at a dose of 3 g/m2 once prior to initiation of G-CSF
therapy. Results: 28 patients underwent stem cell collection. Stem
cell mobilization was attempted with G-CSF alone in 9 instances,
and with CTX1G-CSF in 20 instances (1 patient underwent mobi-
lization with both). In comparison with G-CSF alone, CTX1G-
CSF yielded a significantly greater stem cell collection (mean
CD341 cells collected: 3.78  106/kg vs. 32.33  106/kg, P \
0.0001). Only 33% of patients who attempted stem cell mobiliza-
tion with G-CSF alone obtained sufficient CD341 cell yield vs.
100% of the patients mobilized with CTX1G-CSF (P\ 0.0001).
The extent of BiRD therapy prior to stem cell mobilization ranged
from 2–27 cycles. The number of cycles of BiRD did not signifi-
cantly impact the success rate of stem cell collection (P 5 0.14).
Conclusion: The patients mobilized with CTX1G-CSF had
a higher collection of CD341 cells, and enough stem cells for
two ASCTs were harvested from them. There was no association
between duration of BiRD therapy and successful CD341 cell col-
lection. Thus, lenalidomide-based induction therapy can be contin-
ued until desired tumor reduction goal is achieved, and CTX in
addition to G-CSF should be used to ensure successful stem cell
harvest prior to ASCT.
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AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR MANTLE
CELL LYMPHOMA
Mahindra, A., Copelan, E., Bolwell, B., Rybicki, L., Dean, R.,
Kalaycio, M., Sobecks, R., Ferraro, C., Cherni, K., Pohlman, B.,
Sweetenham, J. Cleveland Clinic, Cleveland, OH.
Background: Mantle cell lymphoma (MCL) is associated with
disappointing results with conventional chemotherapy. The use of
high dose therapy and ASCT for this disease is unclear. We report
here our experience with 61MCL patients (pts) treated with ASCT.
Patients andMethods: 61 pts underwent ASCT forMCL between
7/1996 and 3/2007 using a uniform preparative regimen of busul-
fan, cyclophosphamide and etoposide. 51 pts (84%) had Stage IV
disease. 48% of the pts were in first complete remission (CR1),
5% were in CR2, 25% in first partial remission (PR1), 10% in
PR2 and remaining were CR/PR 31. Results:Median age at diag-
nosis was 56 yrs (range 33–71) and at transplant was 59 yrs (range
34–72). Median time from diagnosis to ASCT was 8.3 months
(range 4.6–81). There were no deaths within 100 days of ASCT.
23 pts (38%) relapsed after ASCTat amedian of 19.8months (range
2.6–59.6). On multivariable analysis, patients transplanted in CR2
or PR2 compared to CR1 or PR1 (p\0.001, HR 5.72) had a higher
risk of relapse.
Poster Session I 65Of note, among these 23 pts, 11 are alive at a median of
40.5 months (range 13.5–91) after relapse. Two of these patients
subsequently underwent a nonmyeloablative transplant and are
alive - one at 51.7 months and the other at 18.7 months after non-
myeloablative transplant. The nine other pts have received a spec-
trum of chemotherapy agents after relapse. Conclusion: ASCT is
a safe and effective strategy in the management of MCL. The en-
couraging results observed for pts undergoing ASCT in first remis-
sion merit further prospective evaluation. A subset of pts tends to
have a prolonged survival despite relapsing after ASCT.The clinical
characteristics pre and post ASCT do not reveal an obvious cause
for the same. It is likely that the ongoing work in gene expression
profiling and study of signaling pathways may identify multiple mo-
lecularly and clinically distinct diseases within what is considered
a single disease entity.
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LONG TERM FOLLOW-UP REPORT ON AUTOLOGOUS STEM CELL
TRANSPLANT (ASCT) FOR MULTIPLE MYELOMA (MM) AND EVALUA-
TION OF PROGNOSTIC FACTORS: PROLONGED SURVIVAL FOR PATIENTS
WITH LOW HEAMTOPOIETIC CELL TRANSPLANTATION-COMORBITD-
ITY INDEX (HCT-CI) SCORE
Farhat,M., Kassar,M., Gregory, S.A., Venugopal, P.,Myint, R., Go, A.,
Maciejewski, J., Fung, H.C. Rush University Medical Center, Chicago,
IL.
Background:Up-front ASCT is the standard of care for eligible
patients with symptomatic MM. However, there is a lack of long
term follow up data on patient with multiple myeloma from time
of diagnosis.Objective: Evaluation of prognostic factors including
the HCT-CI on mortality risk after autologous stem cell transplant
(ASCT) inmultiplemyeloma (MM).Methods:Weconduct a retro-
spective analysis on 79 patients (pts) with multiple myeloma whom
been followed since original diagnosis between 01/1983 to 12/2003.
The median time from diagnosis to ASCT was 7.6 months. All of
which underwent ASCT in our institution with a median follow
up after ASCT of 45 months. All pts received with induction che-
motherapy before ASCT consisting of various combinations of vin-
cristine, adriamycin, dexamethasone, thalidomide, melphalan,
BCNU, and cyclophospamide. The median CD34 cells collected
was 5.05  106/Kg, with a median hospital stay at transplant of 17
days. Pts were also retrospectively assigned scores based on the
HCT-CI. Definitions of comorbidities were previously reported
(Sorror et. al. Blood 2005; 106:2912). Results: The group com-
prised 50% male with a median age was 55 years (38 – 73). 55 pts
had single transplant and 24 pts had a tandem ASCT. The majority
of pts had IgG myeloma (62 pts.). Comorbidities index showed an
HCT-CI score of 0 in 30%, 1 in 30%, 2–8 in 40% of the pts,
with a median score of 1.77. 20 patients died with only one due to
treatment related mortality (TRM). Pts were categorized into 2
groups: low-risk (scores of 0–1), 46 pts. High-risk (scores 2–8), 33
pts. Neither age, gender, hospital during at transplant, prior
chemo-regimen, or pre-conditioning regiment, amount of CD34
cell collected, nor myeloma subtype, had an significant impact on
OS. By using Kaplan meier survival estimates, the 5 yrs overall sur-
vival (OS) from time of diagnosis comparing the low risk and high
risk group using the HCT-CI, were 82% and 53% respectively (P
5 0.03). Using a cox regression model, the low risk group has a sur-
vival advantage (HR5 2.69, P5 0.03). The medianOS for the high
risk group was 63.7 month while it was not reached for the low risk
group.Conclusion:We conclude that in this cohort with adequate
follow-up: 1)HCT-CI score is the only predictive factor for survival
irrespective of other compounding factors and 2) prolonged survival
can be achieved in the subgroup of pts with low HCT-CI score.
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PHASE I/II TRIAL OF BORTEZOMIB MAINTENANCE FOLLOWING AUTOL-
OGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION AS
TREATMENT FOR INTERMEDIATE- AND ADVANCED-STAGE MULTIPLE
MYELOMA
Schiller, G.J., Liao, M., Sohn, J.P., Malone, R., Bartoni, K.,
Habtemariam, B., Paquette, R., De Vos, S., Territo, M. University of
California, Los Angeles, Los Angeles, CA.Pts with intermediate- and advanced-stage multiple myeloma
were assigned to maintenance therapy with bortezomib beginning
aminimumof 3 and amaximumof 4mos after the day of autologous
PBPC transplantation following a standard preparative regimen of
high-dose melphalan. Eligibility for the initiation of maintenance
required nl organ function with post-transplant neutrophil and plt
recovery. Cohorts of 3 pts each were entered at 1 of 3 dose levels
of bortezomib (1.0, 1.3, and 1.6 mg/m2) given IV q wk for 3 wks fol-
lowed by a 1-wk rest period constituting 1 treatment cycle for a total
of 8 cycles. To-date, 29 pts were eligible for study treatment and 23
pts received at least 1 dose of maintenance. The median t from di-
agnosis to transplant was 11.4 mos and the median t from autolo-
gous transplant to the initiation of bortezomib maintenance was
3.7 mos. Protocol adherence was excellent with only 1 pt missing
the final dose of treatment and 1 other pt discontinuing therapy
due to personal reasons. After completion of the Phase I portion
of the study, the DLT was determined to be 1.6 mg/m2 based on
grade 3 diarrhea in 2 pts. All subsequent pts entered were treated
at the MTD of 1.3 mg/m2. Other, non-dose-limiting toxicities in-
cluded thrombocytopenia, neuropathy, anemia, fatigue, neutrope-
nia, musculoskeletal pain, nausea, herpes zoster reactivation,
diarrhea, edema, and cough. Disease assessment consisted of serum
and urine PEP and bone surveys as well as bone marrow aspiration
for those pts with nonsecretory myeloma. 2 pts required termina-
tion of the study drug due to unacceptable side effects. 2 separate
pts terminated the study due to disease progression. 1 additional
pt discontinued further study treatments due to personal reasons.
All 23 pts are eligible for response assessment. 13 pts continue to
be followed for disease recurrence in the post-treatment period
while 4 others continue on treatment. After a median follow-up
from transplantation of 17.1 mos, 6 pts have relapsed while none
have died of recurrent myeloma. The current median relapse-free
survival is 15.8 mos. This phase I/II trial demonstrates that bortezo-
mib can be safely administered as maintenance after conventional
autologous PBPC transplantationwith anMTDof 1.3mg/m2 given
3 times per month for 8 mos. These preliminary results, when com-
pared to published results of autologous transplantation for mye-
loma, suggest that bortezomib maintenance may favorably impact
t-to-recurrence.177
THE ‘‘SIDE-POPULATION’’ IN HUMAN LYMPHOMA CELL LINES HAVE IN-
CREASED CHEMO-RESISTANCE, STEM-LIKE PROPERTIES, AS A TARGET
FOR IMMUNOTHERAPY
Shafer, J.A.1,2, Bollard, C.M.1,2, Leen, A.M.1,2, Rooney, C.M.1,2,
Brenner, M.K.1,2, Foster, A.E.1,2. 1Baylor College of Medicine; 2Baylor
College of Medicine, Houston, TX.
We previously demonstrated that cancer cells contain a distinct
‘‘side-population’’ (SP), characterized by active transport of
Hoechst fluorescent dye. The mechanisms responsible for Hoechst
efflux also contribute to resistance to chemotherapy. This popula-
tion has been shown to be enriched for tumor initiating cells in sev-
eral human cancer models. We hypothesize that targeting the
cancer ‘‘SP’’ cells using immunotherapy will eliminate the cell pop-
ulation least sensitive to chemotherapy and enriched for tumor re-
populating potential which may prevent relapse. In this study we
characterize SP cells in ten Human Lymphoma Cell Lines. We
show that that 5 of the 10 lymphoma cell lines tested (HDLM2,
L428, Ramos, Toledo, Karpas) had a distinct SP ranging from
0.8–2%. In vitro these SP cells can repopulate both the SP and
non-SP cells. Gene expression analysis of the SP showed increased
expression of ABCG2 and other ABC transporters that mediate
both the transport of Hoechst dye and other drugs including
some chemotherapeutic agents out of the cell. Further, we demon-
strated that cell lines with a SP are resistant to the chemotherapeutic
drug gemcitabine, and within these lines it the SP cells that are pref-
erentially resistant to this agent. The cell lines that did not have SP
showed either complete or partial sensitivity to this drug. In addi-
tion, we demonstrated that the SP population is enriched for the
cancer testis antigen’s MAGE-4, SSX2 and NY-ESO. These anti-
gens are attractive targets for cytotoxic T lymphocyte therapy since:
they are immunogenic, have restricted expression in normal tissues,
and are expressed in many cancers. These tumor antigens may
